Herantis Extends HER-096 Phase 2 Treatment Period to Nine Months
Herantis Pharma extended the placebo-controlled treatment period for its HER-096 Phase 2 study to nine months.
Herantis Pharma extended the placebo-controlled treatment period for its HER-096 Phase 2 study to nine months.